IMRX
Price
$6.75
Change
+$0.06 (+0.90%)
Updated
Dec 3, 04:59 PM (EDT)
Capitalization
457.8M
97 days until earnings call
Intraday BUY SELL Signals
SPRB
Price
$90.16
Change
+$0.96 (+1.08%)
Updated
Dec 3, 04:59 PM (EDT)
Capitalization
89.64M
Intraday BUY SELL Signals
Interact to see
Advertisement

IMRX vs SPRB

Header iconIMRX vs SPRB Comparison
Open Charts IMRX vs SPRBBanner chart's image
Immuneering
Price$6.75
Change+$0.06 (+0.90%)
Volume$4.66K
Capitalization457.8M
Spruce Biosciences
Price$90.16
Change+$0.96 (+1.08%)
Volume$1.09K
Capitalization89.64M
IMRX vs SPRB Comparison Chart in %
IMRX
Daily Signal:
Gain/Loss:
SPRB
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
IMRX vs. SPRB commentary
Dec 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMRX is a Hold and SPRB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 04, 2025
Stock price -- (IMRX: $6.70 vs. SPRB: $90.15)
Brand notoriety: IMRX and SPRB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IMRX: 29% vs. SPRB: 5%
Market capitalization -- IMRX: $457.8M vs. SPRB: $89.64M
IMRX [@Biotechnology] is valued at $457.8M. SPRB’s [@Biotechnology] market capitalization is $89.64M. The market cap for tickers in the [@Biotechnology] industry ranges from $107.98B to $0. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IMRX’s FA Score shows that 0 FA rating(s) are green whileSPRB’s FA Score has 0 green FA rating(s).

  • IMRX’s FA Score: 0 green, 5 red.
  • SPRB’s FA Score: 0 green, 5 red.
According to our system of comparison, SPRB is a better buy in the long-term than IMRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IMRX’s TA Score shows that 6 TA indicator(s) are bullish while SPRB’s TA Score has 2 bullish TA indicator(s).

  • IMRX’s TA Score: 6 bullish, 3 bearish.
  • SPRB’s TA Score: 2 bullish, 4 bearish.
According to our system of comparison, IMRX is a better buy in the short-term than SPRB.

Price Growth

IMRX (@Biotechnology) experienced а -9.95% price change this week, while SPRB (@Biotechnology) price change was -13.79% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.32%. For the same industry, the average monthly price growth was +1.23%, and the average quarterly price growth was +54.93%.

Reported Earning Dates

IMRX is expected to report earnings on Mar 11, 2026.

Industries' Descriptions

@Biotechnology (+0.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IMRX($458M) has a higher market cap than SPRB($89.6M). IMRX YTD gains are higher at: 204.545 vs. SPRB (186.190). SPRB has higher annual earnings (EBITDA): -48.11M vs. IMRX (-63.7M). SPRB has higher revenues than IMRX: SPRB (1.3M) vs IMRX (0).
IMRXSPRBIMRX / SPRB
Capitalization458M89.6M511%
EBITDA-63.7M-48.11M132%
Gain YTD204.545186.190110%
P/E RatioN/AN/A-
Revenue01.3M-
Total Cash26.4MN/A-
Total Debt4MN/A-
TECHNICAL ANALYSIS
Technical Analysis
IMRXSPRB
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 6 days ago
89%
Bullish Trend 6 days ago
86%
Momentum
ODDS (%)
Bullish Trend 6 days ago
86%
Bearish Trend 6 days ago
88%
MACD
ODDS (%)
Bullish Trend 6 days ago
80%
N/A
TrendWeek
ODDS (%)
Bullish Trend 6 days ago
85%
Bearish Trend 6 days ago
89%
TrendMonth
ODDS (%)
Bullish Trend 6 days ago
85%
Bearish Trend 6 days ago
89%
Advances
ODDS (%)
Bullish Trend 6 days ago
89%
Bullish Trend 10 days ago
77%
Declines
ODDS (%)
Bearish Trend 20 days ago
90%
Bearish Trend 14 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 6 days ago
87%
N/A
Aroon
ODDS (%)
Bullish Trend 6 days ago
85%
Bearish Trend 6 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
IMRX
Daily Signal:
Gain/Loss:
SPRB
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CGACX12.67N/A
N/A
Calvert Global Energy Solutions C
FRIFX12.30N/A
N/A
Fidelity Real Estate Income
MPLIX16.26N/A
N/A
Praxis International Index I
ASILX16.35N/A
N/A
AB Select US Long/Short I
MGKCX13.23N/A
N/A
Morgan Stanley Global Permanence C

IMRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMRX has been loosely correlated with SPRB. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if IMRX jumps, then SPRB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMRX
1D Price
Change %
IMRX100%
-5.50%
SPRB - IMRX
52%
Loosely correlated
+8.47%
APVO - IMRX
33%
Poorly correlated
-3.79%
ALGS - IMRX
30%
Poorly correlated
+0.11%
ORMP - IMRX
29%
Poorly correlated
+0.36%
SRRK - IMRX
29%
Poorly correlated
-2.12%
More

SPRB and

Correlation & Price change

A.I.dvisor indicates that over the last year, SPRB has been loosely correlated with NEVPF. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if SPRB jumps, then NEVPF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SPRB
1D Price
Change %
SPRB100%
+8.47%
NEVPF - SPRB
61%
Loosely correlated
N/A
IMRX - SPRB
52%
Loosely correlated
-5.50%
MLEC - SPRB
51%
Loosely correlated
+15.52%
IMCR - SPRB
37%
Loosely correlated
-3.78%
VYNE - SPRB
35%
Loosely correlated
-2.00%
More